Journal Mobile Options
Table of Contents
Vol. 80, No. 1-4, 2003
Issue release date: January 2004
Meet Am Soc Stereotact Funct Neurosurg, New York, N.Y., 2003. Stereotact Funct Neurosurg 2003;80:43–47

Effect of Motor Improvement on Quality of Life following Subthalamic Stimulation Is Mediated by Changes in Depressive Symptomatology

Tröster A.I. · Fields J.A. · Wilkinson S. · Pahwa R. · Koller W.C. · Lyons K.E.
Departments of aPsychiatry and Behavioral Sciences, and bNeurological Surgery, University of Washington, Seattle, Wash., cDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, N.C., dDivision of Neurosurgery, eDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kans., and fDepartment of Neurology, Mount Sinai School of Medicine, New York, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Subthalamic deep brain stimulation (STN-DBS) for Parkinson’s disease (PD) improves motor symptoms and quality of life (QOL). Because depression is a potent correlate of QOL, and STN-DBS may be associated with changes in mood, this study sought to determine whether QOL improvement is a direct or indirect consequence of motor improvement. Methods: 26 patients with PD, free of dementia and major depression, who consecutively underwent bilateral, microelectrode-guided STN-DBS, underwent preoperative and 3-month postoperative neuropsychological evaluation, including measures of QOL (PD Questionnaire –39) and depressive symptoms (Beck Depression Inventory). Results: Motor score in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III) improved significantly with STN-DBS relative to preoperative ‘on’ and ‘off’ scores, as did QOL and depressive symptoms. Extent of QOL improvement tended to be associated with improvement in motor score from presurgical on to postsurgical on stimulation and on medication state. QOL improvement was significantly related to amelioration of depressive symptoms. Partial correlations revealed that the association between QOL improvement and depression remained significant when influence of motor improvement on QOL and depression was controlled for. The motor-QOL association was no longer significant when effects of depression were controlled for. Conclusions: Significant QOL improvements after STN-DBS are associated with improved motor ‘on’ state and depressive symptoms. The influence of motor improvement on QOL may be largely indirect by reducing depression.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Meyers AR, Gage H, Hendricks A: Health-related quality of life in neurology. Arch Neurol 2000;57:1224–1227.
  2. Pollak P, Fraix V, Krack P, Moro E, Mendes A, Chabardes S, Koudsie A, Benabid AL: Treatment results: Parkinson’s disease. Mov Disord 2002;17(suppl 3):S75–S83.
  3. Daniele A, Albanese A, Contarino MF, Zinzi P, Barbier A, Gasparini F, Romito LM, Bentivoglio AR, Scerrati M: Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:175–182.
  4. Lagrange E, Krack P, Moro E, Ardouin C, Van Blercom N, Chabardes S, Benabid AL, Pollak P: Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002;59:1976–1978.
  5. Just H, Ostergaard K: Health-related quality of life in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 2002;17:539–545.
  6. Martínez-Martín P, Valldeoriola F, Tolosa E, Pilleri M, Molinuevo JL, Rumià J, Ferrer E: Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord 2002;17:372–377.
  7. Global Parkinson’s Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson’s disease: Results from an international survey. Mov Disord 2002;17:60–67.
  8. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, Du Moncel ST, Bonnet AM, Pidoux B, Dormont D, Cornu P, Agid Y: Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701–707.
  9. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D, Cornu P, Pidoux B, Samson Y, Agid Y: Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999;340:1476–1480.
  10. Berney A, Vingerhoets F, Perrin A, Guex P, Villemure J-G, Burkhard PR, Benkelfat C, Ghika J: Effect on mood of subthalamic DBS for Parkinson’s disease: A consecutive series of 24 patients. Neurology 2002;59:1427–1429.
  11. Doshi PK, Chhaya N, Bhatt MH: Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord 2002;17:1084–1085.
  12. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group. JAMA 2002;287:455–463.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50